Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 4350358)

Published in Oncotarget on December 30, 2014

Authors

Hui Zhao1, Claire M Faltermeier1, Lori Mendelsohn2, Peggy L Porter3, Bruce E Clurman4, James M Roberts1

Author Affiliations

1: Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
2: Biology Department, Whitman College, Walla Walla, Washington, USA.
3: Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
4: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Articles cited by this

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83

Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77

A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41

Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell (1996) 7.69

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer (2008) 6.22

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med (2002) 5.79

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med (2002) 5.25

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med (2002) 4.69

A new description of cellular quiescence. PLoS Biol (2006) 3.56

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36

p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev (2004) 3.16

Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev (2007) 3.00

p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell (2005) 2.65

Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science (2008) 2.29

Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell (1998) 2.29

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol (1993) 2.15

A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev (2006) 2.05

Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol (2003) 1.85

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem (2003) 1.56

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol (2002) 1.55

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res (2006) 1.53

A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.47

Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest (1999) 1.46

Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res (2007) 1.35

Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res (2004) 1.30

Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res (2005) 1.20

Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res (2009) 1.13

Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene (2011) 1.12

Significance of skp2 expression in primary breast cancer. Clin Cancer Res (2006) 1.02

Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene (2009) 0.99

Prognostic significance of cytoplasmic p27 expression in human melanoma. Cancer Epidemiol Biomarkers Prev (2011) 0.98

Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol (2010) 0.97

A mechanism misregulating p27 in tumors discovered in a functional genomic screen. PLoS Genet (2007) 0.92

Cytoplasmic p27Kip1 counteracts the pro-apoptotic function of the open conformation of PTEN by retention and destabilization of PTEN outside of the nucleus. Cell Signal (2011) 0.85

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Ann Oncol (2012) 0.83